Selective accumulation of platinum and formation of platinum-DNA adducts in hepatocellular carcinoma after transarterial chemoembolization with miriplatin

Hepatology Research

Volumn 43, Issue 10, 2013, Pages 1093-1099

  Yasui, Kohichiroh ^a   Takashima, Hidetaka ^c   Miyagawa, Masami ^d   Miyazawa, Kazuhiro ^c   Ochiai, Toshiya ^b   Mukaisho, Ken ichi ^e   Amaike, Hisashi ^d   Ueda, Kazushige ^d   Morikawa, Junichiro ^c   Otsuji, Eigo ^b   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Nagahama Red Cross Hospital   (Japan)

^d Kameoka Municipal Hospital   (Japan)

^e SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Hepatocellular carcinoma; Miriplatin; Platinum; Platinum DNA adduct; Transcatheter arterial chemoembolization

Indexed keywords

IODINATED POPPYSEED OIL; MIRIPLATIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CASE REPORT; CHEMOEMBOLIZATION; CONTROLLED STUDY; DNA ADDUCT; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DNA INTERACTION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; MASS SPECTROMETRY; PLATINUM DNA ADDUCT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME;

EID: 84885086034     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12059     Document Type: Article

References (22)

1. Bosch FX, Ribes J, Cleries R etal. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.
2. European Association for the Study of the Liver, European Organisation for Research, Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
4. Maeda M, Uchida NA, Sasaki T. Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res 1986; 77: 523-525.
5. Fujiyama S, Shibata J, Maeda S etal. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Br J Cancer 2003; 89: 1614-1619.
6. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs 2004; 22: 169-176.
7. Okusaka T, Kasugai H, Ishii H etal. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. Invest New Drugs 2012; 30: 2015-2025.
8. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279.
9. Terheggen PM, Emondt JY, Floot BG etal. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res 1990; 50: 3556-3561.
10. Chua TC, Liauw W, Saxena A etal. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int 2010; 30: 166-174.
11. Couinaud C. Le Foie. Etudes Anatomique et Chirurgivales. Paris: Masson, 1957.
12. The Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 3rd English edn. Tokyo: Kanehara & Co., Ltd., 2010.
13. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
14. Oken MM, Creech RH, Tormey DC etal. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
15. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
16. Bruix J, Sherman M, Practice Guidelines Committee AASLD. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
17. Hanada M, Baba A, Tsutsumishita Y etal. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol 2009; 64: 473-483.
18. Jarvis IW, Meczes EL, Thomas HD etal. Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues. Biochem Pharmacol 2012; 83: 69-77.
19. Hoebers FJ, Pluim D, Verheij M etal. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). Int J Cancer 2006; 119: 750-756.
20. Hoebers FJ, Pluim D, Hart AA etal. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemother Pharmacol 2008; 61: 1075-1081.
21. Los G, Blommaert A, Barton R etal. Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Cancer Chemother Pharmacol 1995; 37: 150-154.
22. Zamboni WC, Gervais AC, Egorin MJ etal. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res 2002; 8: 2992-2999.